The Impact of Single-shot Adductor Canal Block Versus Continuous Femoral Nerve Block on Rehabilitation After Total Knee Replacement (AdORe - ACB)

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Total knee replacement (TKR) is considered the most effective and safe method of radical treatment of late stages of knee osteoarthritis. A well-known problem of TKR is a severe postoperative pain syndrome, which is observed in more than 50% of patients. Femoral nerve block (FNB) is the gold standard for continuous postoperative analgesia after total knee replacement, as it is effective in reducing the frequency of use of opioid analgetics and reduce the duration of hospitalization. At the same time, the negative effect of this method is the motor blockade of the quadriceps femoris muscle which leads to functional impairment and is associated with an increased risk of falling. Adductor canal block (ACB) provides adequate analgesia comparable to femoral nerve block. Moreover, ACB doesn't affect the motor function of the quadriceps femoris muscle. The possibility of enhanced recovery after total knee replacement is the reason to compare single-shot adductor canal block and continuous femoral nerve block.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18

• Planned primary total knee replacement

• Planned neuraxial anesthesia

• Written informed consent

Locations
Other Locations
Russian Federation
Clinical Hospital on Yauza
RECRUITING
Moscow
Contact Information
Primary
Valery Likhvantsev
lik0704@gmail.com
+79036235982
Backup
Levan Berikashvili
levan.berikashvili@mail.ru
+79263308968
Time Frame
Start Date: 2024-02-03
Estimated Completion Date: 2028-07-01
Participants
Target number of participants: 220
Treatments
Experimental: Single-shot adductor canal block
Active_comparator: Continuous femoral nerve block
Sponsors
Leads: Negovsky Reanimatology Research Institute

This content was sourced from clinicaltrials.gov